Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

Whether space, health, technology or environment, here are the issues in science that the editors of Scientific American are ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

CHRISTMAS… it’s THE ultimate eating challenge. But for the millions of us reportedly on weight loss jabs, what misery awaits?

Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...

US Ag Secretaru says bill marks a significant step forward in strengthening school nutrition and supporting America’s dairy ...